Ceftaroline Fosamil Patent Expiration
Ceftaroline Fosamil is Used for treating bacterial infections. It was first introduced by Abbvie Inc
Ceftaroline Fosamil Patents
Given below is the list of patents protecting Ceftaroline Fosamil, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Teflaro | US8247400 | Cephem compounds useful for the treatment of bacterial infections | Feb 10, 2031 | Abbvie |
| Teflaro | US9629861 | Compositions and methods for treating bacterial infections using ceftaroline | Sep 21, 2030 | Abbvie |
| Teflaro | US6906055 | Phosphonocephem compound |
Dec 15, 2021
(Expired) | Abbvie |
| Teflaro | US7419973 | Phosphonocephem compound |
Dec 15, 2021
(Expired) | Abbvie |
| Teflaro | US6417175 | Phosphonocephem derivatives, process for the preparation of the same, and use thereof |
Dec 17, 2018
(Expired) | Abbvie |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ceftaroline Fosamil's patents.
Latest Legal Activities on Ceftaroline Fosamil's Patents
Given below is the list recent legal activities going on the following patents of Ceftaroline Fosamil.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Jan, 2024 | US8247400(Litigated) |
| Electronic Review Critical | 27 Jun, 2023 | US7419973 |
| Change in Power of Attorney (May Include Associate POA) Critical | 27 Jun, 2023 | US7419973 |
| Email Notification Critical | 27 Jun, 2023 | US7419973 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Oct, 2020 | US9629861 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Feb, 2020 | US8247400(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Feb, 2020 | US7419973 |
| Mail Pub Notice re 312 amendment | 19 Jun, 2017 | US9629861 |
| Post Issue Communication - Certificate of Correction | 15 Jun, 2017 | US9629861 |
| POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION | 15 Jun, 2017 | US9629861 |
Ceftaroline Fosamil's Family Patents
Explore Our Curated Drug Screens
Ceftaroline Fosamil Generic API Manufacturers
Several generic applications have been filed for Ceftaroline Fosamil.
Given below is the list of companies who have filed for Ceftaroline Fosamil generic, along with the locations of their manufacturing plants worldwide.
1. APOTEX
Apotex Inc has filed for 2 different strengths of generic version for Ceftaroline Fosamil. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 400MG/VIAL | powder | Discontinued | INTRAVENOUS | N/A | Sep 21, 2021 |
| 600MG/VIAL | powder | Discontinued | INTRAVENOUS | N/A | Sep 21, 2021 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||
| Canada |
| |||||||||||||
| India |
| |||||||||||||